SERINC5

Across TCGA pan-cancer cohorts, SERINC5 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of SERINC5’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where SERINC5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SERINC5 is over-expressed in tumor, although a few such as KIRC and LUAD show the opposite, repressed pattern.

BRCA, STAD, and UCEC are the cancer types where SERINC5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SERINC5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	II,III,IV	+0.399	<.001	8	view →
STAD	Male	II,III,IV	+1.423	<.001	6	view →
UCEC	All	All	+1.008	.001	6	view →
KIRC	All	II,III,IV	−0.343	.007	6	view →
BLCA	All	III,IV	+1.127	.012	5	view →
THCA	Male	II,III,IV	+0.581	.016	4	view →
LUAD	Female	All	−0.358	.011	4	view →
PRAD	All	All	+1.115	<.001	2	view →
KICH	All	III,IV	−0.927	.028	2	view →
KIRP	Male	All	−0.700	<.001	2	view →
LIHC	All	All	+0.474	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

SERINC5–BRCA

Open the BRCA breakdown →